Oculis Holding AG Ordinary shares logo

Oculis Holding AG Ordinary shares(OCS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$7.06
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for OCS

11/20/2026: OCS (1-star) is currently NOT-A-BUY. Pass it for now.

Oculis Holding AG is a clinical-stage biopharmaceutical company focused on developing innovative ophthalmic and neuro-ophthalmic therapies. Its core strengths lie in proprietary formulation platforms like OPTIREACH that enable non-invasive topical delivery for serious eye conditions, anchored by late-stage candidates such as OCS-01 and OCS-02. The primary investment opportunity centers on potential regulatory approvals that could transform it into a commercial-stage drug provider. However, key risks include ongoing net losses, execution challenges in Phase 3 trials, and intense competition from established pharmaceutical players. The stock suits growth-oriented investors comfortable with high volatility, who should closely monitor upcoming clinical data readouts and regulatory milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitOculis offers high-growth exposure to late-stage clinical biotechnology innovations addressing major ophthalmic markets.
Momentum investorStrong fit while signal remains positiveThe stock frequently experiences sharp price movements around clinical trial readouts and regulatory announcements.
Value investorWeak fitThe company currently generates minimal commercial revenue and substantial net losses typical of clinical-stage biotech firms.
Dividend investorWeak fitOculis pays no dividends, focusing all capital resources on clinical development and corporate expansion.
Low-risk investorWeak fitClinical-stage biotechnology stocks carry inherent binary risks related to clinical trial outcomes and regulatory approvals.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighStock prices fluctuate significantly based on clinical data releases and broader biotech market sentiment.
Valuation riskMedium / highValuation relies heavily on projected future commercial success rather than current earnings or revenue.
Competition risk (ophthalmic pharma and biotech)HighThe company competes with well-funded pharmaceutical companies offering entrenched therapies and standard treatments.
Business qualityMediumWhile backed by proprietary delivery platforms, the business is pre-commercial and lacks a diversified revenue stream.
Dividend incomeLow / noneNo dividend is distributed, making it entirely unsuited for income-focused portfolios.
Execution riskHighSuccessful clinical trial execution and regulatory approvals are vital for the company's survival and growth.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 414.52M USD
Price to earnings Ratio -
1Y Target Price 35.71
Price to earnings Ratio -
1Y Target Price 35.71
Volume (30-day avg) 313.1K shares
Beta 0.29
52 Weeks Range 6.78 - 34.48
Updated Date 11/19/2026
52 Weeks Range 6.78 - 34.48
Updated Date 11/19/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.69

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 21.14%
Avg. Invested days 40
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
OCS receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
OCS has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-10.2%), soft cash generation (FCF margin 0.0%), negative revenue growth (-100.0%).

Financial Health Rating

★★★★★
OCS's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
OCS's growth profile is soft, with the least-weak measure being earnings growth at -10.2% FY2025 versus FY2024. By comparison, while revenue growth (-100.0%, negative) and free-cash-flow growth (-31.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 49.7% and approximately 92.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.52% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

EQT Fund Management S.à r.l. 12.47%
Aberdeen Group PLC 4.09%
Millennium Management LLC 3.67%
Pivotal bioVenture Partners Investment Advisor LLC 2.98%
Citadel Advisors Llc 1.77%

Unit Economics (Per $1K Revenue)

★★★★★
OCS generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.19%

Quantitative Style Profile

★★★★★
OCS has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Early Commercial and Grant RevenuesSmall amounts of revenue derived from early product sales or collaboration/grant agreements in select regions.Revenue is currently negligible because the company is focused on developing drugs rather than selling them at scale.
Future Product Commercialization (Pipeline)Anticipated future sales from proprietary eye drop treatments like OCS-01 and OCS-02 upon regulatory approval.Investors are buying into the future potential of its drug pipeline rather than current cash flow.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 164.01M
Price to Sales(TTM) 442.39
Enterprise Value 164.01M
Price to Sales(TTM) 442.39
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.47
Shares Outstanding 55.72M
Shares Floating 51.59M
Shares Outstanding 55.72M
Shares Floating 51.59M
Percent Insiders 3.52
Percent Institutions 49.66

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.